China trial shows Gilead's drug does not show benefits in COVID-19 patients: Lancet

Credit: Reuters India- Published on April 29, 2020
Gilead Sciences Inc's experimental drug remdesivir does not speed up recovery from COVID-19 compared with placebo in critically-ill, hospitalised patients, according to data from a trial in China published in the Lancet.

You are here

Related videos from verified sources

BayCare taking part in several clinical trials to find treatments, cure for COVID-19 01:29
Credit: ABC Action News - Published 8 hours ago 

Ibuprofen to be tested as treatment to reduce Covid-19 symptoms 00:40
Credit: PA - Press Association STUDIO - Published 10 hours ago 

Related news from verified sources

A trial in China testing Gilead Sciences Inc's antiviral drug, remdesivir, in those with mild symptoms of COVID-19 has been suspended due to a lack of eligible...
on April 15, 2020 • Reuters India

A closely-watched Gilead Sciences Inc experimental antiviral drug failed to help patients with severe COVID-19 in a clinical trial conducted in China, but the...
on April 24, 2020 • Reuters India